Bioinformatics Analysis of Persistent Dysregulated Expression of Genes Involved in HCV‐Induced Neurological Disorders and Liver Injuries After DAA Treatment Through Weighted Gene Co‐Expression Network Analysis

Our findings suggest that DAA treatment does not lead to the normalization of gene transcription patterns in CHC patients up to 6 months after HCV clearance. The non-normalization of neuronal and immune gene expression, along with subsequent changes in the activity of related pathways, may contribute to the persistence or progression of HCV-induced neuropsychiatric disorders and liver injuries after DAA treatment. The identified genes and their altered expression patterns provide novel insights into potential molecular mechanisms underlying disease progression following successful DAA therapy. Furthermore, these genes may serve as candidate biomarkers for monitoring disease progression or as potential targets for therapeutic intervention.